Trial Profile
Probable Alzheimer Type Dementia Compare INM-176 1200~1600mg/Day With Donepezil 5~10mg/Day of Safety and Efficacy to Randomization, Multicenter, Double-blind, Double-dummy, Parallel Phase III Clinical Study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs INM 176 (Primary) ; Donepezil
- Indications Alzheimer's disease; Dementia
- Focus Therapeutic Use
- 10 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jun 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 02 Dec 2010 New trial record